CompoAtlas

PHYTO-BIOPÔLE 13 MIX-CEFA

Food supplement declared in France, declaration No 2024-3-789, decision dated 13 March 2024

PHYTO-BIOPÔLE 13 MIX-CEFA (PHYTO-BIOPÔLE) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).

Brand
PHYTO-BIOPÔLE
Food business operator placing the product on the market
INTERSA LABS S.L.
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Compte-gouttes
Daily dose
2,4 ml
Directions for use
Agiter avant utilisation. Prendre 15 gouttes diluées dans 1/2 verre d'eau, 4 fois par jour.
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Allergie aux dérivés salicylés, Femmes enceintes, Sous anticoagulants, Sous traitement antihypertenseur

Declaration 140057, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Salix alba L.EcorceExtrait fluide hydroalcoolique960 mg
Melissa officinalis L.Parties aériennesExtrait fluide hydroalcoolique360 mg
Chamaemelum nobile (L.) All.FleurExtrait fluide hydroalcoolique240 mg
Alnus glutinosa (L.) Gaertn.Feuille (bourgeon)Macérât hydroglycériné80.4 mg
Chamaemelum nobile (L.) All.Essence (fleur)Distillation6 mg
Citrus aurantium L.Essence (feuille)Distillation6 mg
Lavandula angustifolia Mill.Essence (fleur)Distillation2.4 mg

Other ingredients

eau, Alcool

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne se substitue pas à une alimentation variée et équilibrée et à un mode de vie sain. Conserver hors de la portée des jeunes enfants. Son utilisation est déconseillée aux personnes souffrant d’allergie aux dérivés salicylés. Ne pas utiliser en cas de grossesse ou d'allaitement . Ne pas utiliser en cas de traitement anti-hypertenseur. L'emploi chez les personnes sous traitement anti-coagulant et chez les enfants et les adolescents est déconseillé. Déconseillé en cas d’allergie croisée connue aux Asteraceae. Conserver à l’abri de l’humidité, de la chaleur et de la lumière.Alc. 43% vol.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Salix alba L.
    Read the warning, when it applies and the studies cited

    WILLOW BARK

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have asthma or peptic ulcer disease (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or products containing salicylates (e.g., acetylsalicylic acid or non-steroidal anti-inflammatory drugs) (EMA 2017).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are allergic to salicylates (EMA 2017; Brinker 2010; Wichtl 2004, ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000)

    6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2024

  • Melissa officinalis L.
    Read the warning, when it applies and the studies cited

    LEMON BALM -MELISSA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 April 2024

  • Chamaemelum nobile (L.) All.
    Read the warning, when it applies and the studies cited

    Roman Chamomile - Chamaemelum Nobile

    Route of administration: Oral (Wichtl 2004; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2000; Blumenthal et al. 1998).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : PHYTO-BIOPÔLE

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line